Havrix®: Clinical Trials

6 completed, 1 recruiting, 1 withdrawn. 3 Phase 3, 2 Phase 2, 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 3	3	Completed 3
Phase 2	2	Completed 2
Phase 4	2	Completed 1, Withdrawn 1

Follow Havrix®: new trials by email Literature Review of Havrix® trials Research Report on Havrix®

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study on the Long-Term Persistence of Immunity Induced by Inactivated Hepatitis A Vaccine Healive®, Havrix® - Hepatitis A		Recruiting	Sinovac Biotech Co., Ltd	106	2026-08-02	2026-10-22
Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel Havrix® - Hepatitis A	Phase 4	Withdrawn	GlaxoSmithKline		2018-05-07	2018-03-02
Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine - Healthy Volunteers (Meningococcal Infection)	Phase 3	Completed	Sanofi Pasteur, a Sanofi Company	2627	2018-04-25	2024-10-15
Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults Bexsero®, Havrix® - Meningococcal Serogroup B	Phase 4	Completed	Canadian Immunization Research Network	120	2015-09-01	2019-01-31
Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Hib-MenCY-TT (MenHibrix®), Pediarix®, Rotarix® - Neisseria Meningitidis, Haemophilus Influenzae Type b	Phase 3	Completed	GlaxoSmithKline	600	2014-02-01	2018-09-14
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax® - Rubella, Mumps	Phase 2	Completed	GlaxoSmithKline	1259	2009-06-03	2020-01-03
Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age Priorix-Tetra™ (MMRV vaccine 208136), ProQuad®, Havrix® - Varicella, Rubella	Phase 2	Completed	GlaxoSmithKline	1851	2007-11-20	2018-10-09
Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Havrix®, M-M-R®II, VARIVAX® - Hepatitis A	Phase 3	Completed	GlaxoSmithKline	1474	2003-10-06	2018-07-31

Conditions studied

Hepatitis A (3)  ·  Measles (2)  ·  Mumps (2)  ·  Rubella (2)  ·  Chickenpox (1)  ·  Haemophilus Infections (1)  ·  Meningitis, Meningococcal (1)  ·  Meningococcal Infections (1)

Sponsors

GlaxoSmithKline (5)  ·  Canadian Immunization Research Network (1)  ·  Sanofi Pasteur, a Sanofi Company (1)  ·  Sinovac Biotech Co., Ltd (1)

Countries

United States (5)  ·  Puerto Rico (2)  ·  Canada (1)  ·  China (1)

Top investigators

Joanne M Langley, MD, MSc, FRCPC (1)  ·  Wenguo Xu (1)

Results publications

PMID 28481690, PMID 31270173, PMID 41337697

NIH funding

2018 (1)